soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction of and tirzepatide for patients with type 2 diabetes in clinical practice Frontiers | Cardiovascular Safety and

The content presented in this newsletter is based on publicly available information and sources believed to be reliable

This review summarizes some of the effective data on cosmeceutical peptides that work against intrinsic and extrinsic aging

Existen ensayos clnicos que han evaluado la terapia adyuvante de exenatida con todos los hipoglucemiantes orales, as como con insulina3

GIP/GLP-1 GIP/GLP-1 GIP/GLP-12.5mg5mg()2 (GIP)-1(GLP-1)2GIP/GLP-1 GIPGLP-1 111 12.5mg415mg 5mg42.5mg115mg 6(2.5mg)(5mg)24(7.5mg10mg12.5mg15mg)20236 20225GIP/GLP-16Mounjaro20229 2.5mg5mg() () ()

GHK-Cus gene modulation capacity was documented in a landmark microarray analysis by Pickart et al., identifying 4,000+ gene targets including VEGF upregulation (angiogenesis), SOD2 upregulation (oxidative defense), and downregulation of pro-inflammatory cytokine genes including TNF- and IL-6

Despite the increased glucose utilization, the PPP increases and the entry of pyruvate into the TCA cycle is decreased, which does not produce enough ATP for cardiac energy supply under TAC induction